Page last updated: 2024-10-30

linopirdine and Alzheimer Disease

linopirdine has been researched along with Alzheimer Disease in 10 studies

linopirdine: acetylcholine releasing drug

Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)

Research Excerpts

ExcerptRelevanceReference
"Small differences in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) scores were seen throughout the study favouring linopirdine; at 6 months the ADAS-Cog scores were 20."2.68A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. ( Beattie, BL; Eastwood, MR; Feldman, H; Gauthier, S; Mohr, E; Pryse-Phillips, W; Rockwood, K, 1997)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wilkerson, WW1
Kergaye, AA1
Tam, SW3
Earl, RA2
Zaczek, R4
Teleha, CA1
Fisher, BN2
Maciag, CM2
Marynowski, ME1
Logue, AR2
Tinker, WJ1
Huang, SM1
Chorvat, RJ2
Provan, SD1
Miyamoto, MD1
Kim, YS1
Nibbelink, DW1
Overall, JE1
Aiken, SP1
Brown, BS1
Rockwood, K1
Beattie, BL1
Eastwood, MR1
Feldman, H1
Mohr, E1
Pryse-Phillips, W1
Gauthier, S1
van Dyck, CH1
Lin, CH1
Robinson, R1
Cellar, J1
Smith, EO1
Nelson, JC1
Arnsten, AF1
Hoffer, PB1
Saye, JA1
Pierdomenico, ME1
Rominger, DH1
DeNoble, VJ1
DeNoble, KF1
Spencer, KR1

Reviews

1 review available for linopirdine and Alzheimer Disease

ArticleYear
Pharmacology of the neurotransmitter release enhancer linopirdine (DuP 996), and insights into its mechanism of action.
    Advances in pharmacology (San Diego, Calif.), 1996, Volume: 35

    Topics: Alzheimer Disease; Drug Interactions; Electrophysiology; Indoles; Pyridines

1996

Trials

3 trials available for linopirdine and Alzheimer Disease

ArticleYear
Factor structure and scoring of the SKT test battery.
    Journal of clinical psychology, 1993, Volume: 49, Issue:1

    Topics: Aged; Alzheimer Disease; Attention; Double-Blind Method; Humans; Indoles; Mental Recall; Neuropsycho

1993
A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1997, Volume: 24, Issue:2

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Double-Blind Method; Female; Humans; Indoles;

1997
The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease.
    Psychopharmacology, 1997, Volume: 132, Issue:3

    Topics: Acetylcholine; Aged; Alzheimer Disease; Cerebrovascular Circulation; Female; Humans; Indoles; Male;

1997

Other Studies

6 other studies available for linopirdine and Alzheimer Disease

ArticleYear
3-Substituted, 3-(4-pyridinylmethyl)-1,3-dihydro-1-phenyl-2H-indol-2-ones as acetylcholine release enhancers: synthesis and SAR.
    Journal of medicinal chemistry, 1993, Oct-01, Volume: 36, Issue:20

    Topics: Acetylcholine; Alzheimer Disease; Amnesia; Animals; Avoidance Learning; Corpus Striatum; Hypoxia; In

1993
2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.
    Journal of medicinal chemistry, 1998, Nov-05, Volume: 41, Issue:23

    Topics: Acetylcholine; Alzheimer Disease; Animals; Anthracenes; Drug Evaluation, Preclinical; Hippocampus; I

1998
Linopirdine. A depolarization-activated releaser of transmitters for treatment of dementia.
    Advances in experimental medicine and biology, 1995, Volume: 363

    Topics: Alzheimer Disease; Animals; Behavior, Animal; Indoles; Membrane Potentials; Molecular Structure; Neu

1995
Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction.
    British journal of pharmacology, 1994, Volume: 111, Issue:4

    Topics: 4-Aminopyridine; Acetylcholine; Alzheimer Disease; Animals; Calcium; Dose-Response Relationship, Dru

1994
Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine.
    The Journal of pharmacology and experimental therapeutics, 1998, Volume: 285, Issue:2

    Topics: Acetylcholine; Alzheimer Disease; Animals; Anthracenes; Dose-Response Relationship, Drug; Indoles; M

1998
Protection against hypoxia-induced passive avoidance deficits: interactions between DuP 996 and ketanserin.
    Brain research bulletin, 1991, Volume: 26, Issue:5

    Topics: Alzheimer Disease; Animals; Avoidance Learning; Drug Interactions; Hypoxia; Indoles; Ketanserin; Mal

1991